How is pharmacologic management of panic disorder discontinued?

Updated: Mar 21, 2018
  • Author: Mohammed A Memon, MD; Chief Editor: Randon S Welton, MD  more...
  • Print

In general, pharmacologic management is continued for at least 1 year following an acute response to increase the potential for further reductions in the patient’s panic symptoms as well as to lower the risk for recurrence. [55] Monthly “booster” sessions that target prevention of relapse may also be used. [55]

The decision to taper or discontinue an effective pharmacotherapy must be tailored to the patient and discussed between the patient and clinician, based upon factors including the duration of the patient’s symptom stability, whether current/impeding psychosocial stressors are present, the extent of the patient’s motivation, as well as the potential outcomes following medication taper or discontinuation. [55, 56]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!